AP Biosciences Inc (TPEX:6945)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
54.50
0.00 (0.00%)
Jul 16, 2025, 2:32 PM CST

AP Biosciences Company Description

AP Biosciences Inc, a clinical-stage biopharmaceutical company, researches and develops bispecific antibody drugs for unmet medical needs.

It develops IBI302 that is in phase III clinical trials for the treatment of neovascular age-related macular degeneration; AP505 that is in phase I clinical trials for treating solid tumors; AP203 that is in phase I clinical trial for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous-cell carcinomas; AP402, which is in in the pre-clinical research phase for breast cancer patients; and AP601 that is in pre-clinical research phase for treating lung cancer, pancreatic cancer, bladder cancer, ovarian cancer, and other solid tumors.

The company was founded in 2013 and is based in Taipei City, Taiwan.

AP Biosciences Inc
CountryTaiwan
Founded2013
IndustryBiotechnology
SectorHealthcare
Employees37
CEOJeng-Horng Her

Contact Details

Address:
No. 508, Zhongxiao East Road
Taipei City, 115011
Taiwan
Phone886 2 2653 2886
Websiteapbioinc.com

Stock Details

Ticker Symbol6945
ExchangeTaipei Exchange
Fiscal YearJanuary - December
Reporting CurrencyTWD
ISIN NumberTW0006945009
SIC Code2836

Key Executives

NamePosition
Jeng-Horng HerChief Executive Officer
Vincent HuangChief Financial Officer